Plasma and urinary levels of beta2 microglobulin in rheumatoid arthritis.

Lam

European Journal of Endocrinology

2013

Objective: Serum b-2 microglobulin (B2M) level predicts mortality in chronic kidney disease. Glycation of B2M is cytotoxic and may contribute to the risk of mortality in diabetic patients. Our objective was to evaluate the relationship between B2M and mortality in diabetic patients. Methods: In this prospective study, 896 participants of the Third National Health and Nutrition Examination Survey with diabetes were included in the analysis. Serum B2M level was used in multivariate Cox regression analysis to predict all-cause and diabetes-related mortality. Results: During a median follow-up of 11.8 years (range 0.1-18.2 years) and 9220.5 person/years, 541 (42.4%) and 207 (16.8%) participants died from all causes and diabetes-related causes respectively. One natural-log unit of B2M was significantly associated with all-cause (hazard ratio (HR)Z6.53, 95% CI 2.07-20.6) and diabetes mortality (HRZ7.35, 95% CI 1.01-53.38) after multivariable adjustment. Similar results were obtained when B2M was analyzed as tertiles or in the threshold model (T1CT2 vs T3). Examination of regression splines suggests a linear increase in hazard for mortality with increasing B2M levels. Conclusions: Serum B2M level is a novel predictor of all-cause and diabetes-related mortality in people with diabetes regardless of renal function.

Section: Discussionsupporting

confidence: 50%

Serum β-2 microglobulin predicts mortality in people with diabetes

Lam

European Journal of Endocrinology

2013

“…The same findings are reported by Talal (10) finding a serum concentration of 2.72 _+ 1.04 mg/1 in SSS (rheumatoid arthritis) patients. Michalski (11) reported a serum concentration of 4.12 + 0.38 mg/1 and Manicourt (20) published a range of 1.3-16.8 mg/1. The lowest level in 21 RA patients was 1.3 mg/l.…”

Section: Discussionmentioning

confidence: 97%

Diagnostic significance of salivary levels ofβ2-microglobulin in Sjögren's syndrome

Swaak¹,

Visch²,

Zonneveld³

1988

Clin Rheumatol

To evaluate the diagnostic significance of salivary beta 2m in Sjögren's syndrome we measured salivary beta 2m levels in 19 patients with primary sicca syndrome (PSS), 15 with secondary Sjögren's syndrome (SSS) and compared the results with 20 normal healthy persons. We showed that beta 2m is specifically excreted in the saliva, because in normal saliva the concentration of beta 2m was unrelated to IgA levels. Also in normals, there was no relationship between serum and saliva concentrations of beta 2m. The mean saliva levels of beta 2m were increased in PSS (1.13 +/- 0.58) and SSS (1.39 +/- 0.69) compared with the levels in normals (0.53 +/- 0.22). The determination of beta 2m in the saliva can therefore be used as a noninvasive measurement for the confirmation of the diagnosis Sjögren's syndrome.

Antimicrob Agents Chemother

“…However, it should be stressed that in certain special instances f82m may be increased in the absence of any impairment of GFR (6,13). In these cases, GFR will be underestimated, and lower-than-expected gentamicin serum concentrations will be obtained.…”

Section: Discussionmentioning

confidence: 99%

Plasma beta 2 microglobulin as a means of predicting gentamicin serum concentrations

Valsamis¹,

Brauman²,

Yourassowsky³

1980

Self Cite

A novel and accurate method for predicting gentamicin peak serum concentration is described. The method considers body weight and renal function as determined by the concentration of ,B2 microglobulin in plasma. In 32 subjects whose renal function ranged from normal to severely impaired, the peak serum concentration of gentamicin was more closely correlated with ,B2 microglobulin (r = 0.69) and with creatinine clearance (r = 0.69) than with serum creatinine (r = 0.53). A nomogram was constructed which related plasma /32 microglobulin concentrations and body weight to predicted gentamicin peak serum concentrations. When the nomogram was clinically applied, the predicted peak gentamicin concentrations corresponded closely to the actual measurements obtained (t = 0.64; P is not significant). We suggest that plasma ,B2 microglobulin concentrations compare favorably with serum creatinine values in the prediction of gentamicin peak concentrations in patients with renal impairment.The use of gentamicin is complicated by its narrow margin of safety (4,8,11,12). Gentamicin is distributed in the extracellular fluid, is not catabolized, and is excreted via glomerular filtration by the kidney (11,14